liposomal lurtotecan

ApprovedSmall molecule

Gilead

liposomal lurtotecan is one of 180 small molecule programs targeting Mucormycosis. It is currently in Approved.

Indications

Total Trials

Active Trials

179

Competitors

Pipeline

Status by Indication[3][1]

Indication

MucormycosisActive, not recruiting

NeutropeniaActive, not recruiting

Cryptococcal MeningitisActive, not recruiting

LeishmaniasisActive, not recruiting

AspergillosisActive, not recruiting

Liver TransplantActive, not recruiting

Cutaneous LeishmaniasisActive, not recruiting

CandidiasisActive, not recruiting

Visceral LeishmaniasisActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

MucormycosisPhase 2

Active, not recruiting

NeutropeniaPhase 3

Active, not recruiting

Cryptococcal MeningitisPreclinical

Active, not recruiting

LeishmaniasisPhase 3

Active, not recruiting

AspergillosisPhase 2

Active, not recruiting

Liver TransplantPhase 3

Active, not recruiting

Cutaneous LeishmaniasisPhase 1/Phase 2

Active, not recruiting

CandidiasisPhase 3

Active, not recruiting

Visceral LeishmaniasisPhase 3

Active, not recruiting

Acute Lymphoblastic LeukemiaApproved

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

408 competitors in Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Blincyto

Amgen

Phase 3

45 2

Rituxan

Roche

Phase 3

40 3

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

44 4

Elspar

DDutch Childhood Oncology Group

Phase 3

47 5

Iclusig

Takeda

Phase 3

14 6

Neupogen

EEastern Cooperative Oncology Group

Phase 3

26 7

Cellcept

Roche

Phase 3

9 8

Clolar

GGenzyme, a Sanofi Company

Phase 3

14 9

Eptanemab

UCB

Phase 3

3 10

Prograf

VVeloxis Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Mucormycosis

NCT06756191

Q3 2029

Phase 3Not yet recruiting

Cutaneous Leishmaniasis

NCT07463040

Q4 2031

Phase 3Not yet recruiting

Liposomal Amphotericin B

NCT06525389

Clinical

Trials by Indication[1]

Liposomal Amphotericin B6 trials

Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003938·115 enrolled

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

Not yet recruiting·—·Phase 3·NCT06525389·428 enrolled

A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation

Completed·UUniversity Hospital Muenster·Phase 2·NCT00148148·75 enrolled

Show 3 more trials

Intermittent Liposomal Amphotericin B Primary Prophylaxis

Unknown status·BBayside Health·Phase 2·NCT00451711·60 enrolled

Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00467883·40 enrolled

An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects

Completed·TTaiwan Liposome Company·Phase 1·NCT01652859·36 enrolled

Leishmaniasis3 trials

Treatment of Mucosal Bolivian Leishmaniasis

Recruiting·FFundacion Nacional de Dermatologia·Phase 3·NCT04799236·120 enrolled

Liposomal Amphotericin in Disseminated Leishmaniasis

Completed·HHospital Universitário Professor Edgard Santos·Phase 3·NCT02025491·20 enrolled

Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly

Recruiting·UUniversity of Brasilia·Phase 2/3·NCT06040489·100 enrolled

Treatment3 trials

Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.

Completed·DDrugs for Neglected Diseases·Phase 3·NCT02011958·59 enrolled

Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh

Completed·DDrugs for Neglected Diseases·Phase 3·NCT01122771·602 enrolled

To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar

Completed·BBharat Serums and Vaccines Limited·Phase 3·NCT00876824·500 enrolled

Mucormycosis3 trials

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 2·NCT00419770·20 enrolled

Amphotericin Versus Posaconazole for Pulmonary Mucormycosis

Recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2·NCT05468372·50 enrolled

Antifungal Drugs in Pulmonary Mucormycosis

Not yet recruiting·BBin Cao·Phase 4·NCT06756191·312 enrolled

Cutaneous Leishmaniasis2 trials

Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly

Completed·HHospital Universitário Professor Edgard Santos·Phase 1/2·NCT06449040·28 enrolled

Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)

Not yet recruiting·IInstitute of Tropical Medicine, Belgium·Phase 3·NCT07463040·900 enrolled

15 more indications

Cryptococcal Meningitis2 trials

Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis

Unknown status·TTTY Biopharm·N/A·NCT02136030·84 enrolled

Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis

Unknown status·HHui Bu·Phase 4·NCT02686853·40 enrolled

Acute Lymphoblastic Leukemia2 trials

Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia

Completed· Gilead logo

Gilead·Phase 3·NCT01259713·355 enrolled

ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia

Terminated· Gilead logo

Gilead·Phase 4·NCT00386997·20 enrolled

Visceral Leishmaniasis2 trials

Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis

Completed·—·Phase 3·NCT00628719·400 enrolled

Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil

Terminated·UUniversity of Brasilia·Phase 4·NCT01310738·378 enrolled

Candidiasis1 trial

Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

Completed· Astellas logo

Astellas·Phase 3·NCT00106288·637 enrolled

Aspergillosis1 trial

Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

Terminated· Astellas logo

Astellas·Phase 2·NCT00047827·2 enrolled

Neutropenic Fever1 trial

Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics

Terminated· Gilead logo

Gilead·Phase 4·NCT00421187·20 enrolled

Invasive Fungal Infection1 trial

Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal Infection

Completed·MMedical Research Council·Phase 3·NCT00003315·200 enrolled

Transplant Recipient1 trial

Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients

Completed·FFundacion SEIMC-GESIDA·Phase 4·NCT01303549·61 enrolled

Prophylaxis1 trial

L-AmB_ Retrospective mUlticenter Study on Mycosis prOphylaxis

Enrolling by invitation·IIstituto Giannina Gaslini··NCT06640296·120 enrolled

Safety and Efficacy1 trial

Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL

Terminated·DDrugs for Neglected Diseases·Phase 2·NCT00832208·124 enrolled

Allergic Bronchopulmonary Aspergillosis1 trial

Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).

Completed·PPoitiers University Hospital·Phase 2·NCT02273661·174 enrolled

Invasive Fungal Infections1 trial

Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00418951·120 enrolled

Neutropenia1 trial

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00008359

Liver Transplant1 trial

Liver Transplant European Study Into the Prevention of Fungal Infection

Completed· Astellas logo

Astellas·Phase 3·NCT01058174·350 enrolled

Recurrent Head and Neck Cancer1 trial

Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00022594·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 35 trial records for liposomal lurtotecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — liposomal lurtotecan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for liposomal lurtotecan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Gilead

liposomal lurtotecan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2029

Q4 2031

Trials by Indication[1]

Liposomal Amphotericin B6 trials

Leishmaniasis3 trials

Treatment3 trials

Mucormycosis3 trials

Cutaneous Leishmaniasis2 trials

Cryptococcal Meningitis2 trials

Acute Lymphoblastic Leukemia2 trials

Visceral Leishmaniasis2 trials

Candidiasis1 trial

Aspergillosis1 trial

Neutropenic Fever1 trial

Invasive Fungal Infection1 trial

Transplant Recipient1 trial

Prophylaxis1 trial

Safety and Efficacy1 trial

Allergic Bronchopulmonary Aspergillosis1 trial

Invasive Fungal Infections1 trial

Neutropenia1 trial

Liver Transplant1 trial

Recurrent Head and Neck Cancer1 trial

References

Drug Info

Quick Facts

Related News